Precision-oncology data layer after a Phase 3 mRNA vaccine win
Tempus is still a $20B business trading near $10B
Tempus Data and Applications is generating about $400M of FY26 revenue at roughly 40% growth and 73% gross margins, a SaaS-like profile that typically commands 12-15x sales, or $4.8-6B. Diagnostics is producing about $1.2B, and a conservative 10x versus Guardant at 13x adds $12B, for an $18-20B sum-of-the-parts versus just over $10B today. A successful Phase 3 personalized mRNA cancer vaccine from Moderna and Merck raises the strategic value of the genomic data, diagnostics, and MRD layer Tempus already supplies to that ecosystem.
| Instrument | Side | Target | Reason |
|---|---|---|---|
| TEM | Long | The Data and Applications franchise already looks like a high-growth, high-margin software business, and the diagnostics book is large enough to support a double-digit sales multiple even after a haircut to Guardant. Together that still implies roughly twice the current market cap, while a commercial path for personalized mRNA vaccines increases demand for the genomic and monitoring infrastructure Tempus already operates. |
Themes
The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.